<p>万基遗传公司（NASDAQ:MYGN - 获取免费报告）目前获得了 14 位分析师的共识评级为 “持有”，Marketbeat Ratings 报告称。两位投资分析师给予该股票卖出评级，八位给予持有评级，四位给予买入评级。在过去一年中，发布报告的经纪人对该股票的平均 12 个月目标价格为 10.50 美元。</p>
<p>获取 <strong>Myriad Genetics</strong> 警报：</p>
<ul>
<li>万基遗传因遗传性癌症检测而股价飙升</li>
</ul>
<p>MYGN 已成为多份研究报告的主题。Piper Sandler 将万基遗传的目标价格从 9.00 美元下调至 8.50 美元，并在 11 月 11 日的报告中对该公司给予 “超配” 评级。Weiss Ratings 在周一的报告中重申了对万基遗传股票的 “卖出（d-）” 评级。Cowen 在 11 月 4 日的报告中重申了对万基遗传股票的 “持有” 评级。瑞银集团在 11 月 4 日的研究报告中将万基遗传股票的目标价格从 6.00 美元上调至 8.00 美元，并给予该股票 “中性” 评级。最后，富国银行在 11 月 5 日的报告中将万基遗传股票的目标价格从 6.00 美元上调至 6.50 美元，并给予该公司 “等权重” 评级。</p>
<p><strong>获取我们关于 MYGN 的最新报告</strong></p>
<h2>机构资金流入和流出</h2>
<ul>
<li>精确科学公司为投资者提供了他们所希望的</li>
</ul>
<p>一些机构投资者和对冲基金最近调整了对 MYGN 的持股。先锋集团在第一季度将其在万基遗传的股份增加了 0.7%。先锋集团目前拥有 10,667,755 股该公司股票，价值 94,623,000 美元，此前在上个季度增持了 76,712 股。Glenview Capital Management LLC 在第二季度将其在万基遗传的持股增加了 17.6%。Glenview Capital Management LLC 目前拥有 4,587,407 股该公司股票，价值 24,359,000 美元，此前在上个季度增持了 687,857 股。Jacobs Levy Equity Management Inc. 在第三季度将其在万基遗传的持股增加了 157.0%。Jacobs Levy Equity Management Inc. 目前拥有 2,442,912 股该公司股票，价值 17,662,000 美元，此前在上个季度增持了 1,492,405 股。Qube Research &amp; Technologies Ltd 在第二季度将其在万基遗传的股份增加了 44.7%。Qube Research &amp; Technologies Ltd 目前拥有 2,051,588 股该公司股票，价值 10,894,000 美元，此前在上个季度增持了 633,439 股。最后，Connor Clark &amp; Lunn Investment Management Ltd. 在第二季度将其在万基遗传的持股增加了 50.5%。Connor Clark &amp; Lunn Investment Management Ltd. 目前拥有 1,387,832 股该公司股票，价值 7,369,000 美元，此前在上个季度增持了 465,921 股。对冲基金和其他机构投资者持有该公司 99.02% 的股票。</p>
<h2>万基遗传股票下跌 1.6%</h2>
<p>NASDAQ:MYGN 的股票在周三开盘时为 6.88 美元。该公司的市值为 6.4128 亿美元，市盈率为-1.59，贝塔值为 1.81。该公司的 50 日简单移动平均为 7.35 美元，200 日简单移动平均为 6.37 美元。万基遗传的 1 年最低价为 3.76 美元，1 年最高价为 15.47 美元。该公司的债务与股本比率为 0.32，流动比率为 2.33，速动比率为 2.12。</p>
<p>万基遗传（NASDAQ:MYGN - 获取免费报告）最后一次发布财报是在 1 月 16 日，周二。该公司报告本季度每股收益为（0.19 美元）。万基遗传的股本回报率为-7.11%，净利润率为-48.53%。该公司在本季度的收入为 1.564 亿美元。万基遗传已将其 2023 财年的指导目标设定为每股收益（0.33）-（0.28）美元。分析师平均预测万基遗传在当前年度的每股收益为-0.3 美元。</p>
<h2>关于万基遗传</h2>
<p>（获取免费报告）</p>
<p>万基遗传公司是一家基因检测和精准医疗公司，在美国和国际上开发基因检测。该公司提供用于肿瘤学、女性健康和药物基因组学的分子诊断测试。它还提供 MyRisk 遗传性癌症检测，这是一种评估遗传性癌症风险的 DNA 测序测试；BRACAnalysis CDx 胚系伴随诊断测试，这是一种帮助确定转移性乳腺癌、卵巢癌、转移性胰腺癌和转移性前列腺癌患者治疗方案的 DNA 测序测试，适用于具有有害或疑似有害胚系 BRCA 变异的患者；以及 MyChoice CDx 伴随诊断测试，这是一种确定卵巢癌患者同源重组缺陷状态的肿瘤测试。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过万基遗传</li>
<li>3 只沃伦·巴菲特在动荡时期必买的股票</li>
<li>AI 芯片离不开这两家被低估的科技巨头</li>
<li>深入分析买卖差价</li>
<li>为什么台湾半导体的 6.5% 下跌可能是一个明智的买入机会</li>
<li>3 只股票可以保护你的投资组合免受冠状病毒传播的影响</li>
<li>RTX 在国防订单激增的情况下飙升至历史新高</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVlHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVlHTg"/></p>
<p><em>此即时新闻警报由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在万基遗传吗？</h2>
<p>在你考虑万基遗传之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而万基遗传并不在名单上。</p>
<p>虽然万基遗传目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

万基遗传

<p>万基遗传（Myriad Genetics, Inc.）（纳斯达克代码：MYGN）获得了 14 位分析师的共识 “持有” 评级，评级从卖出到买入不等。平均目标价为 10.50 美元。机构投资者已调整其持股，持有的股份发生了显著变化。该股票开盘价为 6.88 美元，市值为 6.4128 亿美元。公司报告的每股收益（EPS）为负值（-0.19 美元），并将 2023 财年的指导目标设定为（-0.33）至（-0.28）美元的每股收益。万基遗传提供肿瘤学及其他医学领域的基因检测</p>

<p>Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) has received a consensus rating of &#34;Hold&#34; from the fourteen analysts that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $10.50.</p>
<div class="lb-trans"><p>万基遗传公司（NASDAQ:MYGN - 获取免费报告）目前获得了 14 位分析师的共识评级为 “持有”，Marketbeat Ratings 报告称。两位投资分析师给予该股票卖出评级，八位给予持有评级，四位给予买入评级。在过去一年中，发布报告的经纪人对该股票的平均 12 个月目标价格为 10.50 美元。</p>
</div><p>Get <strong>Myriad Genetics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Myriad Genetics</strong> 警报：</p>
</div><ul>
<li>Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests</li>
</ul>
<div class="lb-trans"><ul>
<li>万基遗传因遗传性癌症检测而股价飙升</li>
</ul>
</div><p>MYGN has been the subject of a number of research reports. Piper Sandler lowered their price target on Myriad Genetics from $9.00 to $8.50 and set an &#34;overweight&#34; rating for the company in a report on Tuesday, November 11th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Myriad Genetics in a report on Monday. Cowen reiterated a &#34;hold&#34; rating on shares of Myriad Genetics in a report on Tuesday, November 4th. UBS Group upped their price target on shares of Myriad Genetics from $6.00 to $8.00 and gave the stock a &#34;neutral&#34; rating in a research report on Tuesday, November 4th. Finally, Wells Fargo &amp; Company lifted their price objective on shares of Myriad Genetics from $6.00 to $6.50 and gave the company an &#34;equal weight&#34; rating in a report on Wednesday, November 5th.</p>
<div class="lb-trans"><p>MYGN 已成为多份研究报告的主题。Piper Sandler 将万基遗传的目标价格从 9.00 美元下调至 8.50 美元，并在 11 月 11 日的报告中对该公司给予 “超配” 评级。Weiss Ratings 在周一的报告中重申了对万基遗传股票的 “卖出（d-）” 评级。Cowen 在 11 月 4 日的报告中重申了对万基遗传股票的 “持有” 评级。瑞银集团在 11 月 4 日的研究报告中将万基遗传股票的目标价格从 6.00 美元上调至 8.00 美元，并给予该股票 “中性” 评级。最后，富国银行在 11 月 5 日的报告中将万基遗传股票的目标价格从 6.00 美元上调至 6.50 美元，并给予该公司 “等权重” 评级。</p>
</div><p><strong>Get Our Latest Report on MYGN</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 MYGN 的最新报告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><ul>
<li>Exact Sciences Serves Investors Exactly What They Wished For</li>
</ul>
<div class="lb-trans"><ul>
<li>精确科学公司为投资者提供了他们所希望的</li>
</ul>
</div><p>A number of institutional investors and hedge funds have recently modified their holdings of MYGN. Vanguard Group Inc. boosted its stake in Myriad Genetics by 0.7% in the first quarter. Vanguard Group Inc. now owns 10,667,755 shares of the company's stock valued at $94,623,000 after acquiring an additional 76,712 shares in the last quarter. Glenview Capital Management LLC boosted its position in shares of Myriad Genetics by 17.6% in the 2nd quarter. Glenview Capital Management LLC now owns 4,587,407 shares of the company's stock worth $24,359,000 after purchasing an additional 687,857 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its position in Myriad Genetics by 157.0% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,442,912 shares of the company's stock valued at $17,662,000 after buying an additional 1,492,405 shares in the last quarter. Qube Research &amp; Technologies Ltd raised its stake in Myriad Genetics by 44.7% in the second quarter. Qube Research &amp; Technologies Ltd now owns 2,051,588 shares of the company's stock valued at $10,894,000 after buying an additional 633,439 shares during the last quarter. Finally, Connor Clark &amp; Lunn Investment Management Ltd. boosted its holdings in Myriad Genetics by 50.5% in the second quarter. Connor Clark &amp; Lunn Investment Management Ltd. now owns 1,387,832 shares of the company's stock worth $7,369,000 after acquiring an additional 465,921 shares in the last quarter. Hedge funds and other institutional investors own 99.02% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近调整了对 MYGN 的持股。先锋集团在第一季度将其在万基遗传的股份增加了 0.7%。先锋集团目前拥有 10,667,755 股该公司股票，价值 94,623,000 美元，此前在上个季度增持了 76,712 股。Glenview Capital Management LLC 在第二季度将其在万基遗传的持股增加了 17.6%。Glenview Capital Management LLC 目前拥有 4,587,407 股该公司股票，价值 24,359,000 美元，此前在上个季度增持了 687,857 股。Jacobs Levy Equity Management Inc. 在第三季度将其在万基遗传的持股增加了 157.0%。Jacobs Levy Equity Management Inc. 目前拥有 2,442,912 股该公司股票，价值 17,662,000 美元，此前在上个季度增持了 1,492,405 股。Qube Research &amp; Technologies Ltd 在第二季度将其在万基遗传的股份增加了 44.7%。Qube Research &amp; Technologies Ltd 目前拥有 2,051,588 股该公司股票，价值 10,894,000 美元，此前在上个季度增持了 633,439 股。最后，Connor Clark &amp; Lunn Investment Management Ltd. 在第二季度将其在万基遗传的持股增加了 50.5%。Connor Clark &amp; Lunn Investment Management Ltd. 目前拥有 1,387,832 股该公司股票，价值 7,369,000 美元，此前在上个季度增持了 465,921 股。对冲基金和其他机构投资者持有该公司 99.02% 的股票。</p>
</div><h2>Myriad Genetics Stock Down 1.6%</h2>
<div class="lb-trans"><h2>万基遗传股票下跌 1.6%</h2>
</div><p>Shares of NASDAQ:MYGN opened at $6.88 on Wednesday. The firm has a market capitalization of $641.28 million, a PE ratio of -1.59 and a beta of 1.81. The business has a 50 day simple moving average of $7.35 and a two-hundred day simple moving average of $6.37. Myriad Genetics has a 1 year low of $3.76 and a 1 year high of $15.47. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.33 and a quick ratio of 2.12.</p>
<div class="lb-trans"><p>NASDAQ:MYGN 的股票在周三开盘时为 6.88 美元。该公司的市值为 6.4128 亿美元，市盈率为-1.59，贝塔值为 1.81。该公司的 50 日简单移动平均为 7.35 美元，200 日简单移动平均为 6.37 美元。万基遗传的 1 年最低价为 3.76 美元，1 年最高价为 15.47 美元。该公司的债务与股本比率为 0.32，流动比率为 2.33，速动比率为 2.12。</p>
</div><p>Myriad Genetics (NASDAQ:MYGN - Get Free Report) last released its earnings results on Tuesday, January 16th. The company reported ($0.19) earnings per share for the quarter. Myriad Genetics had a negative return on equity of 7.11% and a negative net margin of 48.53%.The business had revenue of $156.40 million during the quarter. Myriad Genetics has set its FY23 guidance at ($0.33)-($0.28) EPS. On average, equities analysts predict that Myriad Genetics will post -0.3 EPS for the current year.</p>
<div class="lb-trans"><p>万基遗传（NASDAQ:MYGN - 获取免费报告）最后一次发布财报是在 1 月 16 日，周二。该公司报告本季度每股收益为（0.19 美元）。万基遗传的股本回报率为-7.11%，净利润率为-48.53%。该公司在本季度的收入为 1.564 亿美元。万基遗传已将其 2023 财年的指导目标设定为每股收益（0.33）-（0.28）美元。分析师平均预测万基遗传在当前年度的每股收益为-0.3 美元。</p>
</div><h2>About Myriad Genetics</h2>
<div class="lb-trans"><h2>关于万基遗传</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.</p>
<div class="lb-trans"><p>万基遗传公司是一家基因检测和精准医疗公司，在美国和国际上开发基因检测。该公司提供用于肿瘤学、女性健康和药物基因组学的分子诊断测试。它还提供 MyRisk 遗传性癌症检测，这是一种评估遗传性癌症风险的 DNA 测序测试；BRACAnalysis CDx 胚系伴随诊断测试，这是一种帮助确定转移性乳腺癌、卵巢癌、转移性胰腺癌和转移性前列腺癌患者治疗方案的 DNA 测序测试，适用于具有有害或疑似有害胚系 BRCA 变异的患者；以及 MyChoice CDx 伴随诊断测试，这是一种确定卵巢癌患者同源重组缺陷状态的肿瘤测试。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Myriad Genetics</li>
<li>3 Must-Buy Warren Buffett Stocks for Volatile Times</li>
<li>AI Chips Can’t Exist Without These 2 Underrated Tech Giants</li>
<li>A Deeper Look at Bid-Ask Spreads</li>
<li>Why Taiwan Semiconductor's 6.5% Dip Could Be a Smart Buy</li>
<li>3 Stocks to Protect Your Portfolio from the Coronavirus Contagion</li>
<li>RTX Surges to Record Highs as Defense Orders Explode</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过万基遗传</li>
<li>3 只沃伦·巴菲特在动荡时期必买的股票</li>
<li>AI 芯片离不开这两家被低估的科技巨头</li>
<li>深入分析买卖差价</li>
<li>为什么台湾半导体的 6.5% 下跌可能是一个明智的买入机会</li>
<li>3 只股票可以保护你的投资组合免受冠状病毒传播的影响</li>
<li>RTX 在国防订单激增的情况下飙升至历史新高</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVlHTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=MYGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Myriad Genetics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在万基遗传吗？</h2>
</div><p>Before you consider Myriad Genetics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑万基遗传之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Myriad Genetics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而万基遗传并不在名单上。</p>
</div><p>While Myriad Genetics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然万基遗传目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

万基遗传公司（NASDAQ: MYGN）被券商给予平均 “持有” 评级